BioSpace News Archive

PDS Biotechnology Corporation announced that on April 6, 2022 PDS Biotech granted nonstatutory stock options to Robert Imani, M.D., PhD, PDS Biotech’s Vice President Medical Director to purchase 70,000 shares of PDS Biotech common stock.

T-knife Therapeutics, Inc., a biopharmaceutical company dedicated to developing novel therapeutics to fight cancer, announced it is advancing its second TCR-T program, TK-2504, toward the clinic and presented preclinical data on its ability to generate novel TCRs targeting the KRASG12V antigen.

NGM Biopharmaceuticals, Inc., a biotechnology company focused on discovering and developing transformative therapeutics for patients, provided additional detail on two late-breaking poster presentations it will give on Wednesday, April 13, 2022, at the American Association for Cancer Research Annual Meeting.

Nkarta, Inc., a biopharmaceutical company developing engineered natural killer cell therapies to treat cancer, announced its participation at an upcoming investor conference.

Pharmascience Inc. presents its recommendations for encouraging drug repositioning.

NiKang Therapeutics Inc. today announced presentation of preclinical data investigating NKT2152’s mechanism of action, in vivo pharmacokinetic and pharmacodynamic profile, and anti-tumor effect in multiple xenograft models including ccRCC and hepatocellular carcinoma at the American Association for Cancer Research (AACR) Annual Meeting 2022.

Intuitive monitor featuring patient-tailored approach is now in clinical use in select centers in U.S. and Europe LivaNova PLC, a market-leading medical technology and innovation company, announced receipt of regulatory approvals and the start of a targeted commercial launch for the Essenz™ Patient Monitor.

BioCryst Pharmaceuticals, Inc. announced that the company has paused enrollment in clinical trials with BCX9930 while the company investigates elevated serum creatinine levels seen in some patients.

Global Breast Cancer Antibodies Biomarkers & Clinical Trials Insight 2028 Report `Highlights.

This investigation included the association of N-myristoyl transferase (NMT) expression levels with AML patient survival and the in vitro and in vivo demonstration of AML cell killing and tumor reduction with PCLX-001, a proprietary, potent, NMT inhibitor in clinical investigation in Non-Hodgkin’s Lymphoma (NHL) and solid tumor cancer patients.